Key Finding: Sequential immunoradiotherapy (iRT) demonstrated a median overall survival of 20.3 months vs. 16.0 months for concurrent treatment in newly diagnosed advanced NSCLC.
OCEANUS Study: Sequencing Matters in Immunoradiotherapy for Lung Cancer
The OCEANUS study, a real-world analysis published in JAMA Oncology in 2026, provides critical insights into the optimal sequencing of radiotherapy and immune checkpoint inhibitors for patients with advanced non-small cell lung cancer (NSCLC). The study examined outcomes in 335 patients, comparing sequential versus concurrent immunoradiotherapy (iRT) in newly diagnosed patients and evaluating maintenance immunotherapy after radiotherapy in those with refractory disease.
Sequential vs. Concurrent iRT in Newly Diagnosed Disease
The data strongly favors a sequential approach. For patients receiving radiotherapy and immunotherapy for the first time, the survival outcomes were significantly different:
- Median overall survival: 20.3 months (sequential) vs. 16.0 months (concurrent).
- Hazard ratio for death: 0.68, indicating a 32% lower risk of death for the sequential group.
- Three-year overall survival: 40.7% (sequential) vs. 20.3% (concurrent).
The benefit of sequential therapy was most pronounced in specific subgroups. Patients receiving definitive radiotherapy (HR 0.49) and those with locally advanced disease (HR 0.57) saw the most significant advantage. Notably, no significant benefit was observed in the palliative radiotherapy or de novo metastatic subgroups.
Interpretation: The authors suggest that sequential iRT may allow the immune system to recover from radiotherapy-induced lymphodepletion while still capitalizing on increased antigen presentation. This finding aligns with the positive results of the PACIFIC trial (sequential) and contrasts with less favorable outcomes from concurrent strategies like PACIFIC-2 and CheckMate 73L.
Immunotherapy Maintenance in Refractory Disease
Among the 180 patients with refractory disease, the role of restarting immunotherapy after radiotherapy was explored.
- Median overall survival: 11.2 months (maintenance) vs. 6.7 months (no maintenance).
- Hazard ratio for death: 0.72.
- Three-year survival rate: 28.0% (maintenance) vs. 18.6% (no maintenance).
While the survival difference was notable, it was not statistically significant. This suggests that maintenance immunotherapy after radiotherapy may benefit a selected group of patients, but this strategy requires prospective validation before becoming a standard approach.
The Role of Chemotherapy
The study highlights a divergence in chemotherapy's efficacy based on disease stage.
- Newly Diagnosed Advanced Disease: Chemotherapy was associated with a clear survival benefit. The restricted mean survival time (RMST) gain was 4.7 months overall, and this rose to 6.7 months in the concurrent iRT subgroup.
- Refractory Disease: In this setting, chemotherapy did not improve survival, regardless of whether patients received immunotherapy maintenance.
Clinical Implications
- Sequential First: For newly diagnosed advanced NSCLC, sequential immunoradiotherapy—especially when used with definitive radiotherapy—appears preferable to concurrent treatment.
- Maintenance in Refractory Cases: Immunotherapy maintenance after radiotherapy may offer a survival benefit for select patients, but prospective trials are needed to confirm this.
- Chemotherapy's Role: Chemotherapy remains a valuable tool in newly diagnosed advanced disease, but its benefit wanes significantly in the refractory setting.